Skip to main content
SpringerLink
Log in

Cost-of-Illness Studies

Useful for Health Policy?

  • Current Opinion
  • Cost-of-Illness Studies and Health Policy
  • Published:
PharmacoEconomics Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

A sample of cost-of-illness (COI) studies was reviewed, which included studies for specific diseases (‘specific’ studies) as well as those for the entire range of diseases (‘general’ studies).

Theoretically, COI studies may deliver suitable information for health policy and rational healthcare spending. In practice, however, the informative value of ‘specific’ prevalence-based COI studies is very limited. A static picture of costs is presented in these studies, as trends in costs are not being described or explained by factors such as demography, epidemiology and technology. No practical link is offered between COI estimates and economic evaluation. Incidence-based COI studies can provide more relevant information for economic evaluation studies.

It appears more useful to perform general COI studies, as these provide comparable estimates of disease costs and put cost estimates in a total healthcare perspective. Compared with specific COI studies, general COI studies better facilitate the analysis and projection of trends in costs, for example due to aging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy 1987; 8: 317–23

    Article  Google Scholar 

  2. Hodgson TA. Cost of illness studies: no aid to decision-making? Comments on the second opinion by Shiell et al. Health Policy 1989; 11: 57–60

    Article  PubMed  CAS  Google Scholar 

  3. Hodgson TA. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics 1994; 6 (6): 536–52

    Article  PubMed  CAS  Google Scholar 

  4. van Roijen L, Rutten FFH. Cost of illness studies, policy relevance and methods [in Dutch]. T Soc Gezondheidsz 1997; 75: 184–8

    Google Scholar 

  5. Allaire SH, Prashker MJ, Meenan RF. The costs of rheumatoid arthritis. Pharmacoeconomics 1994; 6 (6): 513–22

    Article  PubMed  CAS  Google Scholar 

  6. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J 1996; 9: 636–42

    Article  PubMed  CAS  Google Scholar 

  7. Beeck EF, Roijen Van L, Mackenbach JP. Medical costs and economic production losses due to injuries in the Netherlands. J Trauma Inj Infect Crit Care 1997; 42 (6): 1116–22

    Article  Google Scholar 

  8. Brown RE, Miller B, Taylor WR, et al. Health-care expenditures for tuberculosis in the United States. Arch Intern Med 1995; 155: 1595–600

    Article  PubMed  CAS  Google Scholar 

  9. Evers SMAA, Engel GL, Ament AJHA. Cost of stroke in the Netherlands from a societal perspective. Stroke 1997; 28: 1375–81

    Article  PubMed  CAS  Google Scholar 

  10. Franco K, Tamburino M, Campbell N, et al. The added costs of depression to medical care, Pharmacoeconomics 1995; 7 (4): 284–91

    Article  PubMed  CAS  Google Scholar 

  11. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54 (11): 405–18

    PubMed  CAS  Google Scholar 

  12. Jönsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 16: 665–73

    Article  Google Scholar 

  13. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997; 19: 128–38

    Article  PubMed  CAS  Google Scholar 

  14. Krahn MD, Berka C, Langlois P, et al. Direct and indirect costs of asthma in Canada 1990. Can Med Assosc J 1996; 154 (6): 821–31

    CAS  Google Scholar 

  15. Lane R, McDonald G. Reducing the economic burden of depression. Int Clin Psychopharmacol 1994; 9: 229–43

    Article  PubMed  CAS  Google Scholar 

  16. Lissovoy de G, Lazarus SS. The economic cost of migraine. Neurology 1994; 44 Suppl. 4: s56–62

    Google Scholar 

  17. Magnusson S. Treatment of rheumatoid arthritis: does it affect society’s cost for the disease? Br J Rheumatol 1996; 35: 791–5

    Article  PubMed  CAS  Google Scholar 

  18. Malone DC, Lawson KA, Smith DH, et al. A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 99 (1): 22–7

    PubMed  CAS  Google Scholar 

  19. Max W. The cost of alzheimer’s disease. Pharmacoeconomics 1996; 9 (1): 5–10

    Article  PubMed  CAS  Google Scholar 

  20. McIntosh E. The cost of rheumatoid arthritis. Br J Rheumatol 1996; 35: 781–90

    Article  PubMed  CAS  Google Scholar 

  21. Mellis CM, Peat JK, Woolcock AJ. The cost of asthma. Pharmacoeconomics 1993; 3 (3): 205–19

    Article  PubMed  CAS  Google Scholar 

  22. Midgard R, Riise T, Nyland H. Impairment, disability and handicap in multiple sclerosis. J Neurol 1996; 243: 337–44

    Article  PubMed  CAS  Google Scholar 

  23. Rupp A. The economic consequences of not treating depression. Br J Psychiatry 1995; 166: 29–33

    Article  Google Scholar 

  24. Simell TT, Sintonen H, Hahl J, et al. Costs of insulin-dependent diabetes mellitus. Pharmacoeconomics 1996; 9 (1): 24–38

    Article  PubMed  CAS  Google Scholar 

  25. Stoller MK. Economic effects of insomnia. Clin Ther 1994; 16: 873–97

    PubMed  CAS  Google Scholar 

  26. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia. Pharmacoeconomics 1995; 8 (3): 199–222

    Article  PubMed  CAS  Google Scholar 

  27. Weiss KB, Sullivan SD. Socio-economic burden of asthma, allergy, and other atopic illnesses. Pediatr Allergy Immunol 1994; 5 Suppl. 1: 7–12

    Article  Google Scholar 

  28. Williams R, Dickson RA. Economics of schizophrenia. Can J Psychiatry 1995; 40: s60–7

    PubMed  CAS  Google Scholar 

  29. Warner DC, McCandless RR, De Nino LA, et al. Costs of diabetes in Texas, 1992. Diabetes Care 1996; 19: 1416–9

    Article  PubMed  CAS  Google Scholar 

  30. Yelin E, Callahan LF. The economic cost and social and psychological impact of musculoskeletal conditions. Arthritis Rheum 1995; 38: 1351–62

    Article  PubMed  CAS  Google Scholar 

  31. Koopmanschap MA, Rutten FFH, Ineveld BM, et al. The friction cost method for measuring indirect costs of disease. J Health Econ 1995; 14: 171–89

    Article  PubMed  CAS  Google Scholar 

  32. Koopmanschap MA, Rutten FFH. Indirect costs: the consequences of production loss or increased costs of production. Med Care 1996; 34 (12): DS59–68

    PubMed  CAS  Google Scholar 

  33. Drummond MF, O’Brien BJ, Stoddard GL, et al. Methods for economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997

  34. Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996

  35. Canadian Coordinating Office of Health Technology Assessment (CCOHTA). Guidelines for economic evaluations of pharmaceuticals: Canada. Ottawa: CCOHTA, 1994

    Google Scholar 

  36. Commonwealth of Australia. Guidelines for the pharmaceutical industry on preparation of submissions to the Pharmaceutical Benefits Advisory Committee: including submissions involving economic analysis. Woden: Australian Department of Health, Housing and Community Services, 1990

    Google Scholar 

  37. Health Care Economics Consensus Group. German recommendations on health care cost analysis: Hannover Consensus. PharmacoEcon Outcomes News 1996; 56: 4–6

    Google Scholar 

  38. Mathers C, Penm R, Carter R, et al. Health system costs of diseases and injury in Australia 1993-94: an analysis of costs, services use and mortality for major disease and injury groups. Canberra: Australian Institute of Health and Welfare, 1998

    Google Scholar 

  39. Moore R, Mao Y, Zhang J, et al. Economic burden of illness in Canada, 1993. Ottawa: Ministry of Public Works and Government Services, 1997

    Google Scholar 

  40. National Health Service (NHS) Executive. Burdens of disease: a discussion document. Wetherby: Office for National Statistics, 1996

    Google Scholar 

  41. Polder JJ, Meerding WJ, Koopmanschap MA, et al. Costs of diseases in the Netherlands 1994 [in Dutch]. Rotterdam: Erasmus University, 1997.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for Medical Technology Assessment (IMTA), Erasmus University Rotterdam, P.O. Box 1738, 3000 DR, Rotterdam, The Netherlands

    Marc A. Koopmanschap

Authors
  1. Marc A. Koopmanschap
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marc A. Koopmanschap.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Koopmanschap, M.A. Cost-of-Illness Studies. Pharmacoeconomics 14, 143–148 (1998). https://doi.org/10.2165/00019053-199814020-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00019053-199814020-00001

Keywords

Search

Navigation